EICHORPublic-registry site landscape for NCT04751487, “Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)”, a Chronic Obstructive Pulmonary Disease study sponsored by Sanofi. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04751487 (registry record) |
| Study title | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) |
| Official title | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) |
| Sponsor | Sanofi |
| Condition(s) | Chronic Obstructive Pulmonary Disease |
| Phase | PHASE3 |
| Listed sites | 297 |
| Intervention(s) | Itepekimab SAR440340, Placebo |
| Site countries | United States, Argentina, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, Estonia, France, Georgia, Germany |
Patient-friendly overview of this study: eichor.com/study/NCT04751487.
Eichor generates a preliminary site-risk snapshot for NCT04751487 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
